Butte, Advisors

Atul J. Butte, M.D.

Ph.D., Co-Founder, Chair, Scientific Advisory Board

A pediatric endocrinologist by training, Atul is an expert and pioneer in the field of translational bioinformatics. He is an Associate Professor of Pediatrics, and by courtesy, Medicine and Computer Science, at Stanford University and the Lucile Packard Children’s Hospital. He serves on the Board of Directors of the American Medical Informatics Association and on the External Advisory Board of Johnson and Johnson Corporate Office of Science and Technology (COSAT). Dr. Butte is also a scientific founder of Personalis and Carmenta. Atul received his undergraduate degree in Computer Science and medical degree from Brown University, and a Ph.D. in Health Sciences and Technology from Harvard Medical School and MIT.

schadt, Advisors

Eric Schadt, Ph.D.

Scientific Advisory Board

Eric is an expert in the field of integrative biology. He is currently Director of the Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences and the Jean C. and James W. Crystal Professor of Genomics at Mt. Sinai Hospital. Previously, he served as Chief Scientific Officer of Pacific Biosciences, and before PacBio, was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. He is also a founding member of Sage Bionetworks. Eric has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from UCLA, and his Ph.D. in bio-mathematics from UCLA.

Rich-Mazzarella, Advisors

Rich Mazzarella, Ph.D.

Scientific Advisory Board

Rich is responsible for developing technologies and strategies that transform genomic data into actionable intelligence. With more than three decades of experience in diverse fields including biochemistry, cell and molecular biology, immunology, genetics, computational biology and bioinformatics, Mazzarella is Appistry’s guide on the path to turning personalized medicine into a reality. Rich’s vast expertise in genomics research ranges from advancing the human genome project at Washington University, St. Louis, to patenting progressive findings in cancer research while at Pfizer. His experience and education – which includes a Ph.D. in microbiology from Saint Louis University School of Medicine and serving as an instructor at The Institute for Biomedical Computing & The Center for Genetics in Medicine at Washington University – is not only tapped to advance Appistry’s role in life sciences, but also to nurture St. Louis’ leadership role in life sciences, medicine and technology. Editor of a computational and systems book, author of four book chapters and 40 scientific journal articles, Rich is also a talented engineer who has designed and built robots capable of being controlled remotely over the Internet.

Mark-Murcko-border

Mark Murcko, Ph.D.

Scientific Advisory Board

Mark is the Senior Vice President of Strategy at Schrödinger, which focuses on computational chemistry and provides software and services for life sciences and materials research. Prior to joining Schrödinger, he was Vice President, Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals. Dr. Murcko is a co-inventor of Incivek™ (telaprevir), the world’s most widely prescribed HCV protease inhibitor, as well as Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex’s two marketed drugs for HIV. He is also a co-inventor of 8 other clinical candidates in the areas of cancer, inflammation/immunology, and infectious disease and was responsible for starting many of Vertex’s programs in these and other disease areas. Prior to Vertex, Dr. Murcko worked at Merck Sharpe & Dohme, where he helped discover clinical candidates against cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. One of Merck’s development candidates in this area, Trusopt™ (dorzolamide), became the first marketed drug in pharmaceutical history to result from a structure-based drug design program. Dr. Murcko is highly regarded as an innovator and champion of disruptive technologies. He has served on the editorial boards of many scientific publications, including the Journal of Medicinal Chemistry and Drug Discovery Today, and will serve as the Chair of the 2013 Gordon Research Conference in Medicinal Chemistry. He is a co-inventor on more than 40 issued patents and has co-authored more than 85 scientific articles.

Eric-Perakslis-border

Eric Perakslis, Ph.D.

Scientific Advisory Board

Eric is currently the Executive Director of the Center for Biomedical Informatics (CBMI) at Harvard Medical School. Previously, he was the Chief Information Officer and Chief Scientist (Informatics) at the U.S. Food and Drug Administration, where he was responsible for modernizing and enhancing the IT capabilities as well as the in silico scientific capabilities at FDA. Prior to FDA, Eric was Senior Vice President of R&D Information Technology at Johnson & Johnson Pharmaceuticals R&D and was a member of the Corporate Office of Science and Technology. During his thirteen years at J&J, Eric also held the posts of Vice President R&D Informatics, Vice President and Chief Information Officer, Director of Research Information Technology as well as assistant Director and Director of Drug Discovery Research prior to his current role. Before joining J&J, Eric was the Group leader of Scientific Computing at ArQule Inc. and he began his professional career with the Army Corps of Engineers. Eric has a Ph.D. in chemical and biochemical engineering from Drexel University and also holds B.S.ChE and M.S. degrees in chemical engineering. Eric’s current research interests are enterprise knowledge management, patient stratification, healthcare IT and translational informatics with the specific focus precompetitive data sharing, and open source systems globalization.

Nik-Schork-border

Nicholas Schork, Ph.D.

Scientific Advisory Board

Nicholas is a Professor and Director of Human Biology at the J. Craig Venter Institute (JCVI). He is also an adjunct Professor of Psychiatry and Family and Preventive Medicine (Division of Biostatistics) at the University of California, San Diego (UCSD). Prior to joining JCVI, Nicholas was, from 2007-2013, a Professor, Molecular and Experimental Medicine, at The Scripps Research Institute (TSRI), Director of Biostatistics and Bioinformatics at the Scripps Translational Science Institute (STSI), and Director of Research at Scripps Genomic Medicine, a division of Scripps Health. From 2001-2007 Dr. Schork was a Professor of Biostatistics and Psychiatry, and Co-Director of the Center for Human Genetics and Genomics, at UCSD. From 1994-2000, he was an Associate Professor of Epidemiology and Biostatistics at Case Western Reserve University in Cleveland, Ohio, and an Adjunct Associate Professor of Biostatistics at Harvard University. During 1999 and 2000, Nicholas took a sponsored leave of absence from CWRU to conduct research as the Vice President of Statistical Genomics at the French biotechnology company, Genset, where he helped guide efforts to construct the first high-density map of the human genome.

Johann Gudjonsson

Johann Gudjonsson, MD, PhD

Scientific Advisory Board

Dr. Johann Gudjonsson, MD, PhD is an Assistant Professor of Dermatology and the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute at the University of Michigan. Dr. Gudjonsson is a Director of the Dermatology Inpatient Service at the University of Michigan, and his clinical focus is on complex medical dermatology. Dr. Gudjonsson’s primary research is on immunology and genetics of inflammatory skin disorders such as psoriasis. He has published over 80 papers, many in high impact journals including Nature Genetics, Nature Communications, Human Molecular Genetics, Journal of Immunology, and Journal of Investigative Dermatology. He received the Young Investigator Award from the American Academy of Dermatology in 2007 and his work has earned several research awards, including awards from the American Skin Association, the Dermatology Foundation, National Psoriasis Foundation, Doris Duke Foundation and NIH R01 support.

Bill-Baer-border

Bill Baer, M.D.

Clinical Advisory Board

Bill is Medical Director of Research and Innovation at Mercy Health and Executive Director of ClinXus, a subsidiary of Mercy Health. He holds multiple faculty appointments, including Associate Professor, Michigan State University School of Medicine and an adjunct faculty position at the VanAndel Research Institute in pharmacogenetics. He has received numerous honors and awards and serves in various board/medical director capacities with a number of innovative and forward thinking organizations including Metagenics, Inc., Metabolic Solutions Development Company, and Hopen Life Science Ventures. He also served as co-Chair of the Translational Medicine Working Group for the FDA Critical Paths’ Predictive Safety Testing Consortium. Dr. Baer received his M.D. from West Virginia University School of Medicine and did his residency with Michigan State University. He received his BS in Pharmacy from Duquesne University and Pharm D from West Virginia University. He is a longtime practitioner of internal medicine at Grand Valley Medical Specialists.

Suneel-Gupta-border

Suneel Gupta, Ph.D.

Clinical Advisory Board

Suneel is currently the Chief Scientific Officer at Impax Pharmaceuticals, having joined them in 2008. Before IMPAX Pharmaceuticals, Dr. Gupta worked at ALZA Corporation, a wholly-owned subsidiary of Johnson & Johnson, for nearly 20 years, where he was responsible for strategic vision and execution of clinical research and development as Senior Vice President and distinguished research fellow. His research interest focuses on the influence of rate and route of drug delivery to discover new indications, maximize clinical utility and/or effectiveness. Dr. Gupta has an extensive experience in the development of drug delivery based products across many therapeutic areas. He has made significant contributions to development of several drug delivery based products, such as Duragesic®, Durotap®, Nicoderm®, Testoderm®, Effidac®, Covera-HS®, Ditropan-XL®, Concerta®, Ionsys®, Jurnista®, Invega® and Priligy®. Before ALZA, Dr .Gupta worked for about four years at Ciba Geigy (India) in scale-up and manufacturing of several products. He received his Ph.D. from Univ. of Manchester and was a post-doctoral fellow at the University of California, San Francisco. Dr. Gupta is a coauthor on more than 200 research publications and co-inventor on more than 40 patents.

jay_headshot

Pankaj Jay Pasricha, M.D.

Clinical Advisory Board

Jay is Professor of Medicine, and Director, Center for Motility Disorders and Digestive Diseases at Johns Hopkins University School of Medicine and Professor of Innovation Management at Carey Business School at Johns Hopkins. Previously, he was Professor of Medicine and Surgery and Chief, Division of Gastroenterology and Hepatology at Stanford University School of Medicine. He has served on the National Commission on Digestive Diseases, and on the FDA GI Drug Advisory Committee. He has authored more than 200 manuscripts and book chapters, and holds more than two dozen U.S. patents. Jay has co-founded several companies within the GI space including Apollo Endosurgery, Endopace, EnterRx, FAB, NeurogastRx. Jay received his M.D. degree from the All-India Institute of Medical Sciences, New Delhi and is trained in Internal Medicine (Georgetown University-DC General Hospital), Pulmonology (Tufts-New England Medical Center) and Gastroenterology (Johns Hopkins Hospital).

Sam-Saks-border

Samuel R. Saks, M.D.

Clinical Advisory Board

Sam, a board certified oncologist has more than 25 years of experience developing specialty pharmaceutical products. From 2003 to 2009, Dr. Saks served as CEO of Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company he co-founded. Prior to joining Jazz Pharmaceuticals, Dr. Saks held a number of positions at Alza Corporation, which was acquired by Johnson & Johnson in 2001. From 2001 to 2003, he was Company Group Chairman of Alza and served as a member of Johnson & Johnson’s Pharmaceutical Group Operating Committee. From 1992 to 2001, he held various executive positions at Alza, including Senior Vice President, Medical Affairs and Group Vice President, where he was responsible for clinical and commercial activities. He has also held clinical research positions in oncology at Schering-Plough Corporation, XOMA Corporation and Genentech, Inc. From 1987 to 2000, Dr. Saks was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco. From April 2011 until February 2012, Dr. Saks served as interim Chief Medical Officer of Threshold Pharmaceuticals. Dr. Saks also serves as a director of a number of pharmaceutical companies, including TONIX Pharmaceuticals and Auspex Pharmaceuticals. Dr. Saks received a B.S. and an M.D. from the University of Illinois.

Branimir-Sikic-border

Branimir Sikic, M.D.

Clinical Advisory Board

Branimir is professor of medicine in the Divisions of Oncology and Clinical Pharmacology at Stanford University School of Medicine where he has been a faculty member since 1979. He is the Co-Director of the Stanford Center for Clinical and Translational Education and Research, and Director of the Clinical and Translational Research Unit for the university. He served previously as the Associate Director of Clinical Research for the Stanford Cancer Institute. Dr. Sikic has also served for many years as an advisor to the National Cancer Institute. Dr. Sikic is a leader in the pharmacology of anticancer drugs and the development of new cancer therapies. His research spans the spectrum from molecular and genetic approaches in cancer cells to clinical trials in cancer patients. Dr. Sikic’s laboratory seeks to understand mechanisms of drug resistance in cancer cells and to develop more effective therapies. He has made major scientific and clinical contributions to understanding the problem of multidrug resistance in cancer cells. Current research ranges from molecular and genetic studies of drug resistance in cellular models to Phase I and II clinical trials of new anticancer drugs, including multikinase inhibitors, pro-apoptotic drugs, and novel combinations of targeted drugs with standard chemotherapies. Dr. Sikic has authored more than 225 publications, edited two books, and holds a patent on a P-glycoprotein multidrug transporter. He received his undergraduate education at Georgetown University and his M.D. from the University of Chicago.